Drug Trial Radar · NCT05602597
HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI
Last checked: Nov 19, 2026Latest source record: Mar 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
59
Actual
Start
Jun 1, 2022
Primary completion
Aug 6, 2022
Study completion Aug 6, 2022
Sponsor
- Lead sponsor
- HutchmedIndustry
- Sponsor type
- Industry
- First posted
- Nov 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
An open-label study to determine effect of Itraconazole, Fluconazole, Rifampin, and Rabeprazole on the PK of HMPL-689
Conditions
- Relapsed or Refractory Lymphoma
Interventions
Itraconazole 200 mgDrug
Study participants will be administered 200 mg itraconazole by mouth twice daily after the pharmacokinetic blood draw on Day 3 and once daily on Days 4 to 10, inclusive.
Fluconazole 400 mgDrug
Study participants will be administered 400 mg fluconazole by mouth daily on Day 3 after the pharmacokinetic blood draw, and 200 mg fluconazole by mouth daily on Days 4 to 10, inclusive.
Rifampin 600 mgDrug
Study participants will be administered 600 mg rifampin by mouth daily starting on Day 3, after the pharmacokinetic blood draw, and on Days 4 to 11, inclusive.
Rabeprazole 40 mgDrug
Study participants will be administered 40 mg rabeprazole by mouth daily on Day 3, after the pharmacokinetic blood draw, and on Days 4 to 9, inclusive.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC0-tTime frame: From Day 1 to Day 11 (Day 12 for Rifampin)
- AUC0-infTime frame: From Day 1 to Day 11 (Day 12 for Rifampin)
- CmaxTime frame: From Day 1 to Day 11 (Day 12 for Rifampin)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
QPS- Miami
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.